Araştırma Makalesi
BibTex RIS Kaynak Göster

Erken Gebelikte Kullanılan Vajinal, İntramuskuler veya Kombine Progesteronun Serum Progesteron Düzeylerine Etkisinin Karşılaştırılması

Yıl 2020, Cilt: 17 Sayı: 3, 487 - 491, 25.12.2020
https://doi.org/10.35440/hutfd.761669

Öz

Amaç: Erken gebelik haftasında düşük tehdidi endikasyonu altında başlanılan vajinal, intramuskuler (IM) veya kombine (vaginal+ IM) progesteron preparatlarının serum progesteron düzeylerine etkisinin karşılaştırılması.
Materyal ve metod: Aralık 2018- Aralık 2019 tarihleri arasında kliniğimize düşük tehdidi nedeniyle başvuran ve progesteron uygulanan ilk trimester gebeler çalışmaya dahil edildi. Katılımcılar vajinal progesteron, İM progesteron veya vajinal + İM progesteron tedavisi almalarına göre üç gruba ayrıldı. Grupların ilk ilaç dozundan sonraki 3. saat ve 7. günde ölçülen serum progesteron düzeyleri, serum progesteron seviyelerinin optimal değere ulaşım hızları ve uygunlukları karşılaştırıldı.
Bulgular: Çalışmamıza progesteron tedavisi alan 64 hasta katılmıştır. Bunlardan 23 hasta (%35.9) intramuskuler, 19 hasta (%29.7) vajinal, 22 hasta ise (34.4) vajinal + intramuskuler progesteron kullanan hastalardı. Gruplar arasında progesteron başlama haftası, yaş, gravida ve parite özellikleri açısından anlamlı fark bulunmamıştır. Vajinal +İM progesteron kullanan grubun başvuru sırasında progesteron düzeyleri diğer gruplara göre anlamlı derecede düşük saptanmıştır (p = 0.013). Vajinal +İM progesteron kulllanan grubun hem 3. saatteki hem 7.gündeki serum progesteron seviyesindeki artış oranı, diğer iki gruba (vajinal ve IM) oranla anlamlı derecede yüksek bulunmuştur (sırayla p = 0.001, p = 0.006).
Sonuç: Erken gebelik haftalarında düşük tehditi olan hastaların kesin tedavisi yoktur, ancak progesteron tedavisinin son yıllarda önerildiği çalışmalar artmaktadır. Bu çalışmada vajinal+ IM kombine progesteron preparatlarının serum progesteron seviyelerini daha hızlı arttırdığı belirlenmiştir. Fakat konu ile ilgili çalışmamız yeterli olmayıp ek çalışmalara ihtiyaç vardır.

Kaynakça

  • Siriwachirachai T, Jeeraaumponwat T. Effect of Dydrogesterone on Treatment of Threatened Miscarriage: A Systematic Review and Meta-Analyses. Thai J Obstet Gynaecol. 2010;19.
  • Pandian RU. Dydrogesterone in threatened miscarriage: a Malay-sian experience. Maturitas. 2009;65 Suppl 1:S47-50.
  • Weiss JL, Malone FD, Vidaver J, Ball RH, Nyberg DA, Comstock CH, et al. Threatened abortion: A risk factor for poor pregnancy outcome, a population-based screening study. Am J Obstet Gynecol. 2004;190(3):745-50.
  • Qureshi NS. Treatment options for threatened miscarriage. Maturi-tas. 2009;65 Suppl 1:S35-41.
  • Daya S. Luteal support: progestogens for pregnancy protection. Maturitas. 2009;65 Suppl 1:S29-34.
  • Duan L, Yan D, Zeng W, Yang X, Wei Q. Effect of progesterone treatment due to threatened abortion in early pregnancy for obstetric and perinatal outcomes. Early Hum. Dev. 2010;86(1):41-3.
  • Palagiano A, Bulletti C, Pace MC, D DEZ, Cicinelli E, Izzo A. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann N Y Acad Sci. 2004;1034:200-10.
  • Sotiriadis A, Papatheodorou S, Makrydimas G. Threatened miscarri-age: evaluation and management. BMJ (Clinical research ed). 2004;329(7458):152-5.
  • Tien JC, Tan TY. Non-surgical interventions for threatened and recurrent miscarriages. Singapore Med J. 2007;48(12):1074-90; quiz 90.
  • Miranda S, Litwin S, Barrientos G, Szereday L, Chuluyan E, Bartho JS, et al. Dendritic cells therapy confers a protective microenvironment in murine pregnancy. Scand J Immunol. 2006;64(5):493-9.
  • Yassaee F, Mostafaee L. The role of cervical cerclage in pregnancy outcome in women with uterine anomaly. J Reprod Infertil. 2011;12(4):277-9.
  • Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. Progestogen for treating threatened miscarriage. The Cochrane database of systematic reviews. 2011(12):Cd005943.
  • Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol. Endocrinol. 2012;28(12):983-90.
  • Kuon RJ, Shi SQ, Maul H, Sohn C, Balducci J, Maner WL, et al. Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle. Am J Obstet Gynecol. 2010;202(5):455.e1-9.
  • O'Sullivan MD, Hehir MP, O'Brien YM, Morrison JJ. 17 alpha-hydroxyprogesterone caproate vehicle, castor oil, enhances the cont-ractile effect of oxytocin in human myometrium in pregnancy. Am J Obstet Gynecol. 2010;202(5):453.e1-4.
  • Camuzcuoğlu A , Taner C . Erken gebelik kayıplarının değerlendi-rilmesinde ultrasonografi. Harran Üniversitesi Tıp Fakültesi Dergisi. 2015; 12(1): 103-110.
  • Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertil Steril. 2008;89(4):789-92.
  • Shambhavi S, Bagga R, Bansal P, Kalra J, Kumar P. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth. J Obstet Gynaecol . 2018;38(6):800-6.
  • Wahabi HA, Fayed AA, Esmaeil SA, Bahkali KH. Progestogen for treating threatened miscarriage. Cochrane Database of Systematic Reviews. 2018(8).
  • Maliha Sadaf, Abbasi N. Comparison of Efficacy of Oral Dydroges-terone vsIntramuscular Progesterone in terms of duration of cessation of vaginal bleeding in women with Threatened Abortion. Journal of Rawalpindi Medical College (JRMC. 2019;23(4):194-8.
  • Beigi A, Esmailzadeh A, Pirjani R. Comparison of Risk of Preterm Labor between Vaginal Progesterone and17-Alpha-Hydroxy-Progesterone Caproate in Women with Threatened Abortion: A Ran-domized Clinical Trial. Int J Fertil Steril. 2016;10(2):162-8.
  • Ku CW, Allen Jr JC, Lek SM, Chia ML, Tan NS, Tan TC. Serum progesterone distribution in normal pregnancies compared to preg-nancies complicated by threatened miscarriage from 5 to 13 weeks gestation: a prospective cohort study. BMC Pregnancy and Childbirth. 2018;18(1):360.

Comparison of The Effect of Vaginal, Intramuscular or Combined Progesterone on Serum Progesterone Levels in Early Pregnancy

Yıl 2020, Cilt: 17 Sayı: 3, 487 - 491, 25.12.2020
https://doi.org/10.35440/hutfd.761669

Öz

Kaynakça

  • Siriwachirachai T, Jeeraaumponwat T. Effect of Dydrogesterone on Treatment of Threatened Miscarriage: A Systematic Review and Meta-Analyses. Thai J Obstet Gynaecol. 2010;19.
  • Pandian RU. Dydrogesterone in threatened miscarriage: a Malay-sian experience. Maturitas. 2009;65 Suppl 1:S47-50.
  • Weiss JL, Malone FD, Vidaver J, Ball RH, Nyberg DA, Comstock CH, et al. Threatened abortion: A risk factor for poor pregnancy outcome, a population-based screening study. Am J Obstet Gynecol. 2004;190(3):745-50.
  • Qureshi NS. Treatment options for threatened miscarriage. Maturi-tas. 2009;65 Suppl 1:S35-41.
  • Daya S. Luteal support: progestogens for pregnancy protection. Maturitas. 2009;65 Suppl 1:S29-34.
  • Duan L, Yan D, Zeng W, Yang X, Wei Q. Effect of progesterone treatment due to threatened abortion in early pregnancy for obstetric and perinatal outcomes. Early Hum. Dev. 2010;86(1):41-3.
  • Palagiano A, Bulletti C, Pace MC, D DEZ, Cicinelli E, Izzo A. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann N Y Acad Sci. 2004;1034:200-10.
  • Sotiriadis A, Papatheodorou S, Makrydimas G. Threatened miscarri-age: evaluation and management. BMJ (Clinical research ed). 2004;329(7458):152-5.
  • Tien JC, Tan TY. Non-surgical interventions for threatened and recurrent miscarriages. Singapore Med J. 2007;48(12):1074-90; quiz 90.
  • Miranda S, Litwin S, Barrientos G, Szereday L, Chuluyan E, Bartho JS, et al. Dendritic cells therapy confers a protective microenvironment in murine pregnancy. Scand J Immunol. 2006;64(5):493-9.
  • Yassaee F, Mostafaee L. The role of cervical cerclage in pregnancy outcome in women with uterine anomaly. J Reprod Infertil. 2011;12(4):277-9.
  • Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. Progestogen for treating threatened miscarriage. The Cochrane database of systematic reviews. 2011(12):Cd005943.
  • Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol. Endocrinol. 2012;28(12):983-90.
  • Kuon RJ, Shi SQ, Maul H, Sohn C, Balducci J, Maner WL, et al. Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle. Am J Obstet Gynecol. 2010;202(5):455.e1-9.
  • O'Sullivan MD, Hehir MP, O'Brien YM, Morrison JJ. 17 alpha-hydroxyprogesterone caproate vehicle, castor oil, enhances the cont-ractile effect of oxytocin in human myometrium in pregnancy. Am J Obstet Gynecol. 2010;202(5):453.e1-4.
  • Camuzcuoğlu A , Taner C . Erken gebelik kayıplarının değerlendi-rilmesinde ultrasonografi. Harran Üniversitesi Tıp Fakültesi Dergisi. 2015; 12(1): 103-110.
  • Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertil Steril. 2008;89(4):789-92.
  • Shambhavi S, Bagga R, Bansal P, Kalra J, Kumar P. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth. J Obstet Gynaecol . 2018;38(6):800-6.
  • Wahabi HA, Fayed AA, Esmaeil SA, Bahkali KH. Progestogen for treating threatened miscarriage. Cochrane Database of Systematic Reviews. 2018(8).
  • Maliha Sadaf, Abbasi N. Comparison of Efficacy of Oral Dydroges-terone vsIntramuscular Progesterone in terms of duration of cessation of vaginal bleeding in women with Threatened Abortion. Journal of Rawalpindi Medical College (JRMC. 2019;23(4):194-8.
  • Beigi A, Esmailzadeh A, Pirjani R. Comparison of Risk of Preterm Labor between Vaginal Progesterone and17-Alpha-Hydroxy-Progesterone Caproate in Women with Threatened Abortion: A Ran-domized Clinical Trial. Int J Fertil Steril. 2016;10(2):162-8.
  • Ku CW, Allen Jr JC, Lek SM, Chia ML, Tan NS, Tan TC. Serum progesterone distribution in normal pregnancies compared to preg-nancies complicated by threatened miscarriage from 5 to 13 weeks gestation: a prospective cohort study. BMC Pregnancy and Childbirth. 2018;18(1):360.
Toplam 22 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Klinik Tıp Bilimleri
Bölüm Araştırma Makalesi
Yazarlar

Fatih Yağbasan 0000-0001-6206-9976

Mehmet Murat Işıkalan 0000-0002-5766-7063

Mehmet Cengiz Çolakoğlu Bu kişi benim 0000-0003-4518-6016

Yayımlanma Tarihi 25 Aralık 2020
Gönderilme Tarihi 1 Temmuz 2020
Kabul Tarihi 22 Aralık 2020
Yayımlandığı Sayı Yıl 2020 Cilt: 17 Sayı: 3

Kaynak Göster

Vancouver Yağbasan F, Işıkalan MM, Çolakoğlu MC. Erken Gebelikte Kullanılan Vajinal, İntramuskuler veya Kombine Progesteronun Serum Progesteron Düzeylerine Etkisinin Karşılaştırılması. Harran Üniversitesi Tıp Fakültesi Dergisi. 2020;17(3):487-91.

Harran Üniversitesi Tıp Fakültesi Dergisi  / Journal of Harran University Medical Faculty